37 patents
Utility
Tgfbeta Signal Convertor
16 Nov 23
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Benjamin BOYERINAS
Filed: 7 Apr 23
Utility
TCRa HOMING ENDONUCLEASE VARIANTS
9 Nov 23
The present disclosure provides improved genome editing compositions and methods for editing a TCRα gene.
Jordan JARJOUR, Mark POGSON
Filed: 24 Feb 23
Utility
PCSK9 endonuclease variants, compositions, and methods of use
10 Oct 23
The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene.
Jordan Jarjour, Kyle Havens, Michael Certo, Max Echterling
Filed: 4 Oct 18
Utility
Bcma Chimeric Antigen Receptors
5 Oct 23
The disclosure provides improved compositions for adoptive T cell therapies for B cell related conditions.
SHANNON GRANDE CONTRASTANO, EMILY G. KUIPER
Filed: 24 Aug 21
Utility
Multipartite Signaling Proteins and Uses Thereof
14 Sep 23
The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
Jordan Jarjour, Alexander Astrakhan, Michael Certo
Filed: 10 Nov 22
Utility
CBLB endonuclease variants, compositions, and methods of use
22 Aug 23
The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene.
Jordan Jarjour, Kyle Havens, Anne-Rachel Krostag
Filed: 15 Jan 21
Utility
Methods for Manufacturing Viral Vectors
6 Jul 23
The present disclosure provides improved systems and methods for purifying and/or concentrating lentiviral compositions.
BRENT JULIAN COISMAN
Filed: 10 Jun 21
Utility
Mage A4 T Cell Receptors
25 May 23
The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR.
Christian ELLINGER, Daniel SOMMERMEYER, Geoffrey PARSONS, Jasdeep MANN
Filed: 27 Mar 20
Utility
TGFBeta signal convertor
23 May 23
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Benjamin Boyerinas
Filed: 17 Nov 17
Utility
FRB Antibodies
18 May 23
The invention provides anti-FRB antibodies or antigen binding fragments thereof that bind an FRB polypeptide.
ALEXANDER ASTRAKHAN
Filed: 9 Apr 21
Utility
BCMA chimeric antigen receptors
25 Apr 23
The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.
Richard Morgan, Kevin Friedman
Filed: 1 Apr 20
Utility
T Cell Receptors
20 Apr 23
The present disclosure provides improved T cell receptors, polynucleotides, polypeptides, vectors, cells, and methods f using the same.
JASDEEP MANN
Filed: 26 Mar 21
Utility
TCRα homing endonuclease variants
28 Feb 23
The present disclosure provides improved genome editing compositions and methods for editing a TCRα gene.
Jordan Jarjour, Mark Pogson
Filed: 11 Oct 17
Utility
Engineered T Cells
9 Feb 23
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JASDEEP MANN, CHRISTIAN ELLINGER, DANIEL SOMMERMEYER, BENJAMIN BOYERINAS
Filed: 7 May 20
Utility
Anti-bcma Car Antibodies, Conjugates, and Methods of Use
2 Feb 23
The invention provides improved methods for detecting anti-BCMA CAR expression on T cells.
KEVIN FRIEDMAN, MOLLY REED PERKINS
Filed: 16 Dec 20
Utility
Dimerizing Agent Regulated Immunoreceptor Complexes
2 Feb 23
The present disclosure provides adoptive T cell therapies that have improved DARIC architectures for targeting tumor antigens and recruiting TCR signaling complexes for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JORDAN JARJOUR, ALEXANDER ASTRAKHAN, WAI-HANG LEUNG
Filed: 30 Sep 20
Utility
Methods of making T cell compositions
24 Jan 23
The invention provides improved T cell compositions and methods for manufacturing T cells.
Kevin Friedman
Filed: 9 Oct 19
Utility
Multipartite signaling proteins and uses thereof
20 Dec 22
The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
Jordan Jarjour, Alexander Astrakhan, Michael Certo
Filed: 17 Sep 19
Utility
TGFBetaR2 endonuclease variants, compositions, and methods of use
20 Dec 22
The present disclosure provides improved genome editing compositions and methods for editing a TGFβR2 gene.
Jordan Jarjour, Kyle Havens
Filed: 17 Oct 17
Utility
Adoptive Cell Therapy
17 Nov 22
The invention provides improved methods for adoptive cell therapies for the treatment of cancer.
JAMES BRIAN ROTTMAN
Filed: 20 Mar 20